"SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia (SMART-FM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05005351 |
Recruitment Status :
Completed
First Posted : August 13, 2021
Results First Posted : August 1, 2023
Last Update Posted : August 1, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fibromyalgia | Device: Digital ACT Device: Digital Symptom Tracker | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 67 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | "SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia |
Actual Study Start Date : | October 28, 2020 |
Actual Primary Completion Date : | July 9, 2021 |
Actual Study Completion Date : | July 9, 2021 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Digital Acceptance and Commitment Therapy (ACT) |
Device: Digital ACT
Participants in Digital ACT arm complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual. |
Active Comparator: Digital Symptom Tracker |
Device: Digital Symptom Tracker
Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual. |
- Revised Fibromyalgia Impact Questionnaire (FIQ-R) Total Score [ Time Frame: Baseline to Week 12 ]FIQ-R total score ranges between 0-100 with a reduction in score indicating reduced fibromyalgia severity.
- Key Secondary Endpoint of This Clinical Trial - Rate of Patient's Global Impression of Change (PGIC) Responders at Week 12 - Any Improvement [ Time Frame: Week 12 ]PGIC scores included are: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 22 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Subject is 22 to 75 years of age, inclusive
-
Subject has a diagnosis of primary FM as defined by the 2016 American College of Rheumatology Preliminary Diagnostic Criteria for FM, which requires satisfaction of the following criteria:
- Widespread pain index (WPI) ≥7 and symptom severity (SS) scale score ≥5, OR WPI 4-6 and SS scale score ≥9;
- Symptoms have been present at a similar level for at least 3 months;
- Pain must be present in at least 4 out of 5 body regions
- Subject with ongoing treatments should be on stable therapy for 30 days prior to screening appointment.
- Subject is capable of reading and understanding English and has provided written informed consent to participate.
Key Exclusion Criteria:
- Lifetime history of bipolar disorder as assessed by the MINI.
- Current, untreated, major depressive episode and/or anxiety disorders as assessed by the MINI.
- Subject has a BDI-II total score > 25 at either the Screening appointment or Baseline appointment.
- The subject is at increased risk of suicide on the basis of the investigator's judgment, a response > 1 to BDI item #9, or the results of the Columbia-Suicide Severity Rating Scale ("C-SSRS") conducted at Screening or Baseline (i.e., any suicidal behavior during the preceding year or C-SSRS Type 3, 4, or 5 suicidal ideation during the preceding year).
- Subject has any other disease or medical condition that, in the opinion of the Investigator or Sponsor, could endanger the subject, interfere with the evaluation of the study device's efficacy or safety, or compromise the subject's ability to comply with/complete the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05005351
United States, California | |
Excell Research, Inc. | |
Oceanside, California, United States, 92056 | |
Superior Research LLC | |
Sacramento, California, United States, 95831 | |
United States, Florida | |
Clinical Neuroscience Solutions, Inc. | |
Orlando, Florida, United States, 32801 | |
United States, New York | |
Upstate Clinical Research Associates LLC | |
Williamsville, New York, United States, 14221 | |
United States, Ohio | |
University of Cincinnati Physicians Company, LLC | |
Cincinnati, Ohio, United States, 45219 | |
Neuro-Behavioral Clinical Research, Inc. | |
North Canton, Ohio, United States, 44720 | |
United States, Pennsylvania | |
Lehigh Center for Clinical Research | |
Allentown, Pennsylvania, United States, 18104 |
Study Director: | Michael Gendreau, MD | Consulting Chief Medical Officer |
Documents provided by Swing Therapeutics, Inc.:
Publications of Results:
Responsible Party: | Swing Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT05005351 |
Other Study ID Numbers: |
Swing-004 |
First Posted: | August 13, 2021 Key Record Dates |
Results First Posted: | August 1, 2023 |
Last Update Posted: | August 1, 2023 |
Last Verified: | February 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases |
Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases |